---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-020766"
form_type: "8-K"
ticker: "RNGE"
cik: "0001438943"
company_name: "RANGE IMPACT, INC."
filed_at: "2021-08-20T23:59:59+00:00"
generated_at: "2026-06-29T08:37:18.566083+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vitality Biopharma enters $5M equity line at 85% discount with warrants

## Summary
- Shares sold at 85% of lowest 5-day VWAP; warrants at 115% of same VWAP.
- Drawdowns limited to $250K per notice; financing expires Dec 31, 2022 or $5M total.
- Proceeds to advance VBX-100 prodrug preclinical studies and general corporate purposes.
- VBX-100 granted FDA Orphan Drug Designation for pediatric ulcerative colitis.
- Institutional investor's beneficial ownership capped at 9.99% for shares, 4.99% for warrants.

## SEC filing metadata
- accession: 0001493152-21-020766
- form_type: 8-K
- ticker: RNGE
- cik: 0001438943
- company_name: RANGE IMPACT, INC.
- filed_at: 2021-08-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438943/000149315221020766/0001493152-21-020766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438943/000149315221020766/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-020766
- JSON: https://secwatch.observer/filing/0001493152-21-020766.json
- Plain text: https://secwatch.observer/filing/0001493152-21-020766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.